SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates

Company plans to request a multidisciplinary Type B meeting with FDA to discuss NVG-291’s continued

NGEN

Related stories